alefacept


Also found in: Wikipedia.

alefacept

an immunosuppressive agent.
indication This drug is used to treat adults with moderate to severe plaque psoriasis.
contraindication Known hypersensitivity to this drug prohibits its use.
Mentioned in ?
References in periodicals archive ?
Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis.
While Alefacept protects the immune system, the drug helps the body produce its own insulin, which is key for people who are suffering from type one diabetes.
23 ( ANI ): A drug, Alefacept, which is used for treating skin disorder, Psoriasis, has shown promising results for treating some aspects of type 1 diabetes.
Psoriasis therapies and referral criteria; PUVA Therapy for Psoriasis; Alefacept Therapy for Psoriasis; Etanercept and Infliximab for Psoriasis in Adults
She was then started on a 12-week course of the biologic agent alefacept and UVB treatment, which produced a moderate response.
Hsu acknowledged that the guidelines are a bit bold because they directly state, for example, that acitretin doesn't work well for plaque psoriasis, and that evidence is scant to support the use of alefacept to achieve full clearance.
Alefacept is a fully human fusion protein that blocks interaction between LFA-3 on the antigen-presenting cell and CD2 on the T cell or by attracting natural killer lymphocytes to interact with CD2 to yield apoptosis of particular T-cell clones.
Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema.
Alefacept (Amevive[R]; Biogen) was the first biological agent approved for treatment of psoriasis.
Therapeutic effects of a 12-week course of alefacept on nail psoriasis.
Among their topics are the clinical spectrum and severity of psoriasis, the impact of comorbidity on management, topical treatment, monitoring patients treated with efalizumab or alefacept, therapies for childhood psoriasis, managing difficult to treat locations, and future perspectives in treatment.
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliksimab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).